<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04204642</url>
  </required_header>
  <id_info>
    <org_study_id>SENECA</org_study_id>
    <nct_id>NCT04204642</nct_id>
  </id_info>
  <brief_title>SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)</brief_title>
  <acronym>SENECA</acronym>
  <official_title>SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease,&#xD;
      and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly&#xD;
      patients. Although increasingly detected, a number of aspects including the pathophysiology,&#xD;
      the clinical and neuroradiological phenotype and the disease course are still under&#xD;
      investigation. The incomplete knowledge of the disease limits the implementation of evidence&#xD;
      based guidelines on patient's clinical management and the development of treatments able to&#xD;
      prevent or reduce disease progression.&#xD;
&#xD;
      The SENECA (SEarchiNg biomarkErs of Cerebral Angiopathy) project is the first Italian&#xD;
      multicentre cohort study aimed at better defining the disease natural history and identifying&#xD;
      clinical and neuroradiological markers of disease progression. By a multidisciplinary&#xD;
      approach and the collection of a large and well phenotyped series and biorepository of CAA&#xD;
      patients, the study is ultimately expected to improve the diagnosis and the knowledge of CAA&#xD;
      pathophysiological mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SENECA is an Italian multicenter network integrating the experience of neurologists,&#xD;
      neuroradiologists, neuro-ophthalmologists and biologists and allowing the standardized&#xD;
      collection of a well-characterized wide series of sporadic and familial CAA patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and neuroradiological phenotype</measure>
    <time_frame>24 months</time_frame>
    <description>description of the phenotypic characteristics of a large population of CAA patients collected in Italy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of the neuroradiological picture</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of the severity of the neuroradiological picture (presence and site of WMHs, CMBs, cSS, CMIs, EPVS ,global cortical atrophy and SAH)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <arm_group>
    <arm_group_label>Cerebral amyloid angiopathy (CAA)</arm_group_label>
    <description>Cerebral amyloid angiopathy (CAA) patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAA patients data collection</intervention_name>
    <description>Demographic and clinical data of each patient, including index event that led to the diagnosis (cerebrovascular disease, dementia, gait disturbance, TFNE, seizures, headache), vascular risk factors, history of brain injury or neurosurgery, familial history, and pharmacological treatment will be collected by neurologists in charge.</description>
    <arm_group_label>Cerebral amyloid angiopathy (CAA)</arm_group_label>
    <other_name>Prognostic factors evaluation</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A peripheral blood withdrawal for APOE allele screening will be performed in all patients,&#xD;
      after informed consent obtainment. Additionally, cases with early onset clinical&#xD;
      manifestations and/or rapid clinical progression and/or relatives with a diagnosis of CAA or&#xD;
      presenting early onset CAA clinical features will be addressed to the genetic screening of&#xD;
      Amyloid Precursor Protein (APP) and Transthyretin (TTR) gene. A subgroup of patients will&#xD;
      undergo at T0, T1 and T2 a whole venous blood withdrawal, to collect serum and plasma&#xD;
      samples, evaluate the platelet concentration of Aβ40 by thioflavin T (ThT) assay and Western&#xD;
      blot analysis and the inflammatory and endothelial profile of CAA patients by ELISA or&#xD;
      Bio-Plex Panels&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sporadic and familial CAA patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients ≥55 years (with the exception of genetic cases), referred to&#xD;
             the participating centres, with a diagnosis of possible probable and definite&#xD;
             symptomatic or asymptomatic CAA, defined according to the modified Boston&#xD;
             neuroradiological criteria, who had undergone at least one brain MRI (mandatory&#xD;
             requirement for inclusion of the patient in the study) will be recruited.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of other causes of cerebral hemorrhage (brain tumors, arteriovenous&#xD;
             malformations, aneurysms, cavernous angiomas), contraindications to brain MRI,&#xD;
             pregnancy and breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Bersano, MD, Phd</last_name>
    <phone>+39022394</phone>
    <phone_ext>2321</phone_ext>
    <email>anna.bersano@istituto-besta.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renato Mantegazza, MD</last_name>
    <phone>+39022394</phone>
    <phone_ext>2321</phone_ext>
    <email>crc@istituto-besta.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UOC Neurologia 5</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Bersano, MD</last_name>
      <email>anna.bersano@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Anna Bersano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

